Regeneus sounds confident about the licensing of Progenza in Japan. Hopefully the company can meet its target of doing this in H1 18.
It is also nice to read of a company who talks with pride about not diluting its shareholders - a rarity in the junior/micro cap sector as we all know!
Although not mentioned in the article, I'm looking forward to the reporting on the phase 1 immuno-oncology phase 1 cancer vaccine trial with RGSh4k in the next few months too.
The near term news flow should be strong.
RGS Price at posting:
11.0¢ Sentiment: Buy Disclosure: Held
